Mallia Aesthetics Launches 8T3 Essentials Hair Serum and 8T3 Essentials Lash & Brow Serum
Hits:46 Date: 11/5/2025
* BioPAT® Viamass provides high resolution real-time viable capacitance-based biomass measurement directly in the cell culture, enabling direct inline monitoring of cell growth and advanced, precise analysis *Seamless scalability with one biomass monitoring method from small-scale Ambr® experiments through to large-scale single-use Biostat STR® or Biostat® RM runs *The BioPAT® Viamass single-use sensor integrated with Ambr® 250 High Throughput vessels is available now through Sartorius and its global distribution network
ABERYSTWYTH, UK, November 04, 2025 / Biotech Newswire / -- Aber Instruments and Sartorius Stedim Biotech today announced the introduction of the BioPAT® Viamass single-use biomass sensor now fully integrated into Ambr® 250 High Throughput single-use bioreactor vessels. This expansion marks a significant milestone in scaling advanced Process Analytical Technology (PAT) across the Sartorius bioreactor portfolio, including both Biostat STR® Generation 3 and Biostat® RM systems.
Since partnering in 2013, Aber’s capacitance based biomass probe technology has been adapted into a disposable sensor format, achieving parity in performance with the original reusable format and built to be gamma-sterilizable, USP Class VI compliant, and compatible with Sartorius Flexsafe® formats.
Ambr® 250 High Throughput supports at-line integration of a cell counter, metabolite analyser and BioPAT® Spectro Raman analysis, streamlining cell and media analysis based on automated bioreactor sampling. Now, the addition of BioPAT® Viamass provides high resolution real-time viable biomass measurement directly in the cell culture, enabling direct inline monitoring of cell growth and advanced, precise analysis.
This new single-use Viamass solution seamlessly aligns with Sartorius Stedim Biotech's Biostat STR® Generation 3 and Biostat® RM systems:
* Biostat STR® Generation 3 systems (50 L – 2,000 L) already support BioPAT® Viamass for online biomass monitoring, complementing optical pH, DO, BioPAT® Trace sensors and advanced PAT analytics via Biobrain® process automation.
* Biostat® RM (wave-mixed, 1 L – 200 L) similarly supports integrated BioPAT® Viamass combined with other single-use sensors for seed-train scale-out and intensified processes.
Now, the same sensor technology and interfaces from Ambr® 250 High Throughput to Biostat STR® and RM ensure consistent measurement methodology across process development, seed-train intensification, and commercial manufacture.
Matthew Lee, CEO of Aber Instruments, added: “The extension of BioPAT® Viamass into Ambr® 250 High Throughput vessels opens inline biomass monitoring early in development. It bridges the process-scale gap and underpins high throughput PAT as a scalable asset.”
Ambr® 250 High Throughput - Multi-Parallel Bioreactor
Dr. Franziska Jenner, Head of Product Management, Process Development Bioreactors, Sartorius Stedim Biotech, said: “Integrating the disposable BioPAT® Viamass sensor into Ambr® and our larger Biostat STR® and Biostat® RM systems enables true end-to-end PAT continuity. We are thrilled to deliver robust, scalable biomass monitoring to our customers.”
About Aber Instruments
ABER Instruments is the global leader in biomass sensor technology. Its reusable FUTURA platform has served bioprocess industries for years; the new BioPAT® Viamass disposable sensors extend their footprint into fully single-use workflows under partnership with Sartorius.
Visit our Webiste or follow us on LinkedIn.
About Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international partner to the biopharmaceutical industry. As a provider of innovative solutions, the company based in Aubagne, France, helps its customers to manufacture biotech medications, such as cell and gene therapies, more safely, rapidly, and sustainably. The shares of Sartorius Stedim Biotech S.A. are listed on the Euronext Paris. The company has a strong global reach with manufacturing and R&D sites as well as sales entities in Europe, North America, and Asia. Sartorius Stedim Biotech regularly expands its portfolio through acquisitions of complementary technologies. In 2024, the company generated sales revenue of around 2.8 billion euros. More than 9,900 employees work for customers around the globe.